LSIF is lead guarantor in financing round for Prostatype Genomics AB

LSIF is excited to be lead guarantor in this offering. Prostatype Genomics AB has in our view developed a unique gene test, which can significantly improve both the diagnosis and the quality of life for millions of patients with prostate cancer, and we see a bright future for the company once the US validation study confirms what has already been documented in other studies paving the way for reimbursement in the US in the near term. The next 6-12 months can radically change the prospects for Prostatype Genomics AB, and we look forward to supporting the company on this journey.
The prospectus for the offering has today been released here.